We are live on ! Find out more

885 hedge funds and large institutions have $72.3B invested in Biogen in 2014 Q4 according to their latest regulatory filings, with 130 funds opening new positions, 343 increasing their positions, 279 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more first-time investments, than exits

New positions opened: 130 | Existing positions closed: 54

27% more funds holding in top 10

Funds holding in top 10: 4152 (+11)

23% more repeat investments, than reductions

Existing positions increased: 343 | Existing positions reduced: 279

8% more funds holding

Funds holding: 819885 (+66)

2% more capital invested

Capital invested by funds: $71B → $72.3B (+$1.3B)

28% less call options, than puts

Call options by funds: $975M | Put options by funds: $1.36B

Holders
885
Holders Change
+66
Holders Change %
+8.06%
% of All Funds
23.59%
Holding in Top 10
52
Holding in Top 10 Change
+11
Holding in Top 10 Change %
+26.83%
% of All Funds
1.39%
New
130
Increased
343
Reduced
279
Closed
54
Calls
$975M
Puts
$1.36B
Net Calls
-$382M
Net Calls Change
+$97.3M
Name Holding Trade Value Shares
Change
Change in
Stake
HIMCH
201
Hartford Investment Management Co (HIMCO)
Connecticut
$23.3M +$2.28M +7,050 +11%
Fifth Third Bancorp
202
Fifth Third Bancorp
Ohio
$23.2M +$9.89M +30,578 +81%
TG
203
TCW Group
California
$23.2M -$16M -49,450 -42%
GIBU
204
Gulf International Bank (UK)
United Kingdom
$23M +$235K +727 +1%
Neuberger Berman Group
205
Neuberger Berman Group
New York
$22.8M +$18.9M +58,569 +682%
Loomis, Sayles & Company
206
Loomis, Sayles & Company
Massachusetts
$22.7M -$7.27M -22,486 -25%
ABTD
207
Arvest Bank Trust Division
Oklahoma
$22.6M +$425K +1,315 +2%
ASRS
208
Arizona State Retirement System
Arizona
$22.4M +$129K +400 +0.6%
ACM
209
Atlanta Capital Management
Georgia
$22.2M -$19.1M -58,909 -47%
Renaissance Technologies
210
Renaissance Technologies
New York
$22.1M -$8.9M -27,500 -30%
IGIM
211
I.G. Investment Management
Manitoba, Canada
$22.1M +$10.1M +31,292 +93%
PIA
212
Piedmont Investment Advisors
North Carolina
$21.9M -$15.4M -47,614 -42%
GH
213
GAM Holding
Switzerland
$21.7M +$3.48M +10,769 +20%
Mitsubishi UFJ Asset Management
214
Mitsubishi UFJ Asset Management
Japan
$21.2M +$883K +2,728 +5%
BIM
215
BRC Investment Management
Colorado
$21.1M +$2.19M +6,772 +12%
BSA
216
Braun Stacey Associates
New York
$21M +$699K +2,160 +4%
IRF
217
IBM Retirement Fund
New York
$19.8M -$88K -272 -0.5%
Lazard Asset Management
218
Lazard Asset Management
New York
$19.3M +$592K +1,830 +3%
FAF
219
Fjarde Ap-fonden
Sweden
$19.1M -$1.35M -4,187 -7%
EIM
220
ExxonMobil Investment Management
Texas
$18.9M -$708K -2,190 -4%
GF
221
Gabelli Funds
New York
$18.4M -$1.65M -5,100 -9%
Bank of Nova Scotia
222
Bank of Nova Scotia
Ontario, Canada
$18.3M +$16.2M +50,032 +1,270%
Mackenzie Financial
223
Mackenzie Financial
Ontario, Canada
$18.1M -$7.8M -24,110 -31%
ABI
224
Adamant Biomedical Investments
Switzerland
$18.1M -$573K -1,770 -3%
US Bancorp
225
US Bancorp
Minnesota
$17.9M +$3.63M +11,231 +27%

BIIB Hedge Fund Activity: Q4 2014 in Review

885 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2014, worth a combined $72.3B — up 1.8% from $71B a quarter earlier.

Buyers outnumbered sellers: 130 funds opened new BIIB positions and 54 closed out — a net gain of 76 holders — while 343 added to existing stakes and 279 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $326M. The largest seller was Capital Research Global Investors, cutting an estimated $1.67B.

  • 885 institutional investors held Biogen (BIIB) as of Q4 2014, up from 819 in Q3 2014.
  • Funds reported $72.3B of Biogen stock for Q4 2014, up 1.8% quarter-over-quarter.
  • 130 funds opened new Biogen positions in Q4 2014 and 54 closed out, a net change of +76 holders.
  • The largest Biogen buyer in Q4 2014 was Wellington Management Group, an estimated $326M added.
  • The largest Biogen seller in Q4 2014 was Capital Research Global Investors, an estimated $1.67B sold.

Based on aggregated 13F filings for Q4 2014.